TrialBlood2011

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

Mark Levis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.